With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how cap
As large-molecule drugs and weight-loss therapeutics dominate headlines, the pharmaceutical industry faces legislative pressures, funding cuts, and cascading supply chain disruptions.
It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the triple whammy of a Republican majority in the Senate, House of R
The pharma industry's challenge to Medicare drug price negotiation powers continues to rumble on, with three drugmakers asking a US appeals court to revive their lawsuits.
